新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 艾滋病 » 治愈婴儿艾滋病策略的研究

治愈婴儿艾滋病策略的研究

来源:生物谷 2014-06-17 15:59

2014年6月17日讯 /生物谷BIOON/ --当一个艾滋病患儿在他出生的时候就将他的疾病治愈,这将是多么美好的一个设想。而最近发表在《新英格兰医学杂志》上面的文章向大家展现出了这一设想成为现实的可能。同时他们的研究成果也为用一些积极的药物对艾滋病患儿的医治燃起了希望。该研究中,研究人员对一名出生30小时的患儿使用鸡尾酒疗法对其进行治疗,他们称该名儿童为“Mississippi baby”。在该患儿18个月大的时候停止用药。然而,令人兴奋的是,在停止用药很长一段时间内,该患儿的HIV检测信号均为阴性结果。到现在为止,该名患儿已经3周岁了,同样没有显示出任何HIV检测信号和疾病症状。然而,是什么机理帮助患儿战胜艾滋病毒的目前仍不得而知。

美国国立卫生院希望发起一项全球性研究,来验证这一结果。研究人员希望对54名艾滋病感染婴儿在其出生48小时内就对其进行抗逆转录病毒药物的治疗。研究样本来自全美17家儿童医院和另外11个国家的医院或研究机构。在对样本进行一段时间治疗之后,如果在其血液中未检测到HIV阳性,则将停止用药,以观察其后续结果是否与“Mississippi baby”的结果相一致。当然,研究人员表示,一旦发现患者体内再次检测到HIV阳性信号,那么药物治疗将会重新启动以保证对样本的持续性治疗。(生物谷Bioon.com)

详细英文报道:

When an infant born with HIV was reportedly 'cured' of the disease it seemed too good to be true. The success, detailed by researchers in March 2013 and later published in The New England Journal of Medicine, ignited hope that other babies could benefit from the same aggressive drug regimen that the infant received. Through a series of rare circumstances the so-called ‘Mississippi baby’ began standard HIV treatment 30 hours after birth, but the potent drug cocktail regimen was abruptly halted when the child was 18 months old.

Surprisingly, even after treatment stopped the child’s blood plasma continued to show no signs of the virus. The baby is now more than three years old and remains seemingly disease-free. But exactly how that child bested the virus that causes AIDS remains a mystery (see 'Infant's vanquished HIV leaves doctors puzzled').

That’s where the US National Institutes of Health comes in. This month the NIH expects to launch a global study that will attempt to replicate the Mississippi baby results. Researchers plan to identify 54 HIV-positive infants and treat them with standard antiretroviral drugs, beginning treatment within 48 hours of birth. The team plans to enroll HIV-positive infants across 17 hospitals and clinics in the United States and 11 other countries, including Haiti, India, Malawi, South Africa and Thailand.

After patients receive the aggressive drug course for an extended period (likely the first two years of life), researchers will discontinue the therapy if they cannot find any virus in the child’s blood. The babies will then be carefully monitored to see if the virus boomerangs. “Any child enrolled will have the potential to be followed for five years,” says Ellen Gould Chadwick, one of the investigators leading the clinical trial and a professor of paediatrics and infectious diseases at Northwestern University Feinberg School of Medicine in Chicago. If the infection creeps back, the child’s drug treatment will resume.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库